Sustainability & Climate

Designer Hiromi Asai redefines Japanese heritage at Miami Art Week, transforming sacred kimono textiles into sculptural menswear and making a bold market play.

A smart appliance company is upending global expansion by proving that listening to local communities is the key to becoming a brand that truly matters.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

Beneath the glamour of superyacht dining lies a high-stress world. A unique competition is driving innovation in culinary arts and crew wellbeing.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Beyond the headlines of the G7 tech meeting in Montréal lies a blueprint for Canada's health future, impacting everything from AI diagnostics to local care.

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.

Promising long-term data and key regulatory wins position Wugen's allogeneic therapy to disrupt the challenging T-cell cancer treatment landscape.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

Getlink's latest figures show a slowdown in cross-Channel traffic, revealing deep strains in the automotive sector and growing consumer caution.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

A new program uses seismic waves and AI to map soil health at an unprecedented scale and cost, empowering a global movement to heal our planet's foundation.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.